This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Cheryl Lee, and today we'll be discussing a topic that has continued to be controversial. I'm ...

PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 ...

The recommendations were developed by a multidisciplinary task force and are based on a systematic review of literature ...

Surgical removal is generally recommended as the first-line treatment for muscle-invasive bladder cancer (MIBC) for patients considered medically fit. Some patients get radical cystectomy, or total ...

Surgery for advanced bladder cancer includes transurethral resection of the bladder tumor (TURBT) to remove tumors and cystectomy to remove all or part of the bladder, with the choice depending on the ...

For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a curative treatment ...

US FDA accepts and grants priority review status to AstraZeneca’s sBLA for Imfinzi plus neoadjuvant enfortumab vedotin to treat patients with muscle-invasive bladder cancer: Cam ...

The new clinical guideline was developed by a multidisciplinary task force of radiation, medical, and urologic oncologists, a medical physicist, and a patient representative who reviewed published ...

AstraZeneca?s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) was accepted and granted Priority Review in the US for the ...